The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, […]
Summit Overview – Join life science industry leaders in a full day of non-dilutive funding activities at the 11th Annual Non-dilutive Funding Summit, taking place on Wednesday January 13th, 2016 in San Francisco. REGISTRATION This year the summit is proud to host Colonel Russell E. Coleman, Ph.D., Joint Project Manager, Medical Countermeasure Systems Assistant Corps […]
FREEMIND is pleased to announce its sponsorship and invite you to attend Venture Summit | New England being held on December 9th, 2015. ***Special discount – use discount code ” Freemindvip” and receive an additional 10% off of the registration fee! Venture Summit | New England ™ December 9th, 2015 | Hilton, Boston Dedham Where Innovation Meets Capital Friends, […]
NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well. In the upcoming webinar in the series of summer educational webinars FreeMind experts will discuss key cancer […]
Venue: TKP New York Conference Center Location (city and country): New York, US Event Website Biotech and Money New York provides the education, strategies and solutions executives need to enable more effective funding, investment, business planning, partnering and strategic decision making within their business. It’s where life science meets money, investors meet deal flow and industry promote […]
Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical. In the webinar in the series of summer educational webinars FreeMind […]
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage […]
The U-Mechanism is a support mechanism used when there will be substantial Federal scientific or programmatic involvement by granting agency. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities. We are seeing many programs utilizing this type of mechanism, with substantial awards being made to […]
Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations […]
Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) are inviting fundraising life science companies to attend the upcoming Redefining Early Stage Investments (RESI) Conference in Boston on September 16th. The first RESI Conference took place on September 16, 2013, and two years later, following highly successful events in San Francisco and Houston, LSN returns to Boston for the sixth […]